A detailed history of Neuberger Berman Group LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, Neuberger Berman Group LLC holds 10,846 shares of BCAB stock, worth $19,631. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,846
Holding current value
$19,631
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.37 - $3.92 $14,859 - $42,516
10,846 New
10,846 $14,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $65.7M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.